Hot Topic
Hawke’s Bay
So-called penny stock promoters are getting paid thousands of dollars to advertise, or hype, a US-listed company purportedly holding licensing rights to a biotech patent held by a New Zealander.
Therapy Cells Inc (TCEL) shares trade on the OTC “Pink Sheets” Marketplace, the lowest regulated
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Duncan Bridgeman
Wed, 04 Jun 2014
Wed, 04 Jun 2014
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
US stock pumpers target Kiwi-owned biotech patent
38542